Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, announced positive preclinical data of its lung fibrosis candidate. This drug operates through a novel mRNA biology mechanism of action, opening new avenues for treating Idiopathic Pulmonary Fibrosis (IPF) patients.
Utilizing its mRNA Lightning™ Platform, Anima has successfully identified a preclinical candidate operating through a novel mRNA biology mechanism of action, effectively disrupting the transformation of fibroblasts into fully differentiated myofibroblasts. By inhibiting myofibroblasts’ deposition of extracellular matrix, this candidate demonstrates substantial potential in mitigating fibrotic diseases. The candidates’ oral efficacy in mouse IPF models demonstrates a remarkable safety-to-activity margin and superiority to standard-of-care drugs. It significantly reduces collagen production and fibrotic biomarkers in cells and tissue explants derived from IPF patients. Its clean in vitro ADMET profile further underscores its promise as a breakthrough in fibrotic disease treatment.
Also Read: biomodal Delivers the 6-Base Genome with a Powerful New Multiomic Solution, duet evoC
“This recent achievement further validates our approach,” said Yochi Slonim, co-founder and CEO of Anima. “Our platform’s ability to visualize mRNA biology and decode it with AI technology enables a deeper understanding of disease mechanisms, identification of novel targets, and discovery of drugs that can directly modify the disease phenotype.”
Anima’s unique approach is validated by its strategic partnerships with big pharma, including AbbVie, Takeda, and Eli Lilly, and a broad pipeline of discovery programs across Immunology, Oncology, and Neuroscience. Anima’s LightON mRNA | mRNA Biology Masterclass series has become a central forum for over 1,500 industry and academic experts presenting the latest advances in mRNA biology and its applications to drug discovery.
SOURCE: GlobeNewswire
